Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ICLR - Icon Plc


IEX Last Trade
322.04
1.460   0.453%

Share volume: 446,095
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$320.58
1.46
0.46%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
39%
Profitability 33%
Dept financing 39%
Liquidity 59%
Performance 41%
Company vs Stock growth
vs
Performance
5 Days
-0.65%
1 Month
-2.56%
3 Months
-0.27%
6 Months
-0.43%
1 Year
21.25%
2 Year
53.23%
Key data
Stock price
$322.04
P/E Ratio 
37.19
DAY RANGE
N/A - N/A
EPS 
$8.60
52 WEEK RANGE
$221.20 - $347.72
52 WEEK CHANGE
$0.23
MARKET CAP 
26.568 B
YIELD 
N/A
SHARES OUTSTANDING 
82.495 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/23/2024
BETA 
1.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$339,775
AVERAGE 30 VOLUME 
$336,778
Company detail
CEO: Stephen Cutler
Region: US
Website: http://www.iconplc.com/
Employees: 30,437
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.

Recent news